Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Anita Das"'
Autor:
Steven P Gelone, Susanne Paukner, Christian Sandrock, Jennifer Schranz, Anita Das, Thomas M. File, Lisa Goldberg, Ken B. Waites, Jorge E. Vidal, Stefanie Heinrich, Elizabeth Alexander, Gregory J. Moran, Pritty Patel
Publikováno v:
Journal of Global Antimicrobial Resistance. 29:434-443
Background : Lefamulin, a pleuromutilin antibiotic approved for community-acquired bacterial pneumonia (CABP), was evaluated for microbiological efficacy in a prespecified pooled analysis of LEAP 1 and 2 phase 3 clinical trial data in patients with C
Autor:
Christian Sandrock, Susanne Paukner, Thomas M. File, Anita Das, Elizabeth Alexander, Gregory J. Moran, Lisa Goldberg
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Pulmonary Medicine
BMC pulmonary medicine, vol 21, iss 1
BMC Pulmonary Medicine
BMC pulmonary medicine, vol 21, iss 1
Background Lefamulin, a first-in-class pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia (CABP), was noninferior to moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) 1
Autor:
Anita Das, Amy Manley, Paul C. McGovern, Paul B. Eckburg, Julio Ramirez, Evan Tzanis, Courtney Kirsch, Daniel Deck, Marla Curran
Publikováno v:
Open Forum Infectious Diseases. 8
Background Severity/mortality risk scores and disease characteristics may assist in deciding whether patients with community-acquired bacterial pneumonia (CABP) require outpatient treatment or hospitalization. The phase 3 OPTIC (Omadacycline for Pneu
Autor:
Amy Manley, Courtney Kirsch, Paul C. McGovern, Antoni Torres, Lynne Garrity-Ryan, Anita Das, Judith N. Steenbergen, Marla Curran, Paul B. Eckburg, Evan Tzanis
Publikováno v:
International Journal of Infectious Diseases, Vol 104, Iss, Pp 501-509 (2021)
Objective Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (I
Autor:
George H. Talbot, Elyse Seltzer, Thomas M. File, John Saviski, Lisa Goldberg, Wolfgang W Wicha, Leanne B. Gasink, Anita Das, Carolyn Sweeney, Steven P Gelone, Susanne Paukner
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Monotherapy with lefamulin, a novel, pleuromutilin antibiotic with intravenous and oral formulation options, was noninferior to moxifloxacin for efficacy and generally safe and well tolerated for community-acquired bacterial pneumonia (CABP). Lefamul
Autor:
Elizabeth Alexander, Andrew F. Shorr, Lisa Goldberg, Steven P Gelone, Gregory J. Moran, Anita Das, Christian Sandrock, Jennifer Schranz
Publikováno v:
Open Forum Infectious Diseases
Background In the United States, CABP is the second most common cause of hospitalization and a leading cause of infectious death. Patients with chronic obstructive pulmonary disease (COPD)/asthma or diabetes are at risk for CABP and associated mortal
Autor:
Susanne Paukner, Gregory J. Moran, Thomas M. File, Elizabeth Alexander, Lisa Goldberg, Christian Sandrock, Jennifer Schranz, Anita Das, Andrew F. Shorr, Steven P Gelone
Publikováno v:
Open Forum Infectious Diseases
Background LP is associated with severe CABP, rapid onset, and high morbidity/mortality. Poor outcomes in CABP have been linked to receiving inappropriate empiric therapy or delayed treatment (tx). LEF, a novel IV/oral pleuromutilin, demonstrated eff
Autor:
Elizabeth Alexander, Thomas M. File, Jennifer Schranz, Steven P Gelone, Anita Das, Christian Sandrock, Gregory J. Moran
Publikováno v:
Open Forum Infectious Diseases
Background Efficacy and safety of LEF were shown in 2 noninferiority trials (LEAP 1/2) vs. MOX in adults with CABP. We assessed the efficacy of LEF by visit based on a pooled analyses of LEAP 1/2 data. Methods In LEAP 1, PORT III–V patients (patien
Autor:
Thomas M File, Lisa Goldberg, Anita Das, Carolyn Sweeney, John Saviski, Steven P Gelone, Elyse Seltzer, Susanne Paukner, Wolfgang W Wicha, George H Talbot, Leanne B Gasink
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 69(11)
Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy an
Autor:
Dirkie Johanna Van Rensburg, Prabhavathi Fernandes, Carlos Barrera, Anita Das, Ismail Mitha, Pablo Alexis Doreski, Kay Clark, Kara Keedy, Jose Flores-Figueroa, Barbara Rewerska, Brian D. Jamieson, Amanda Sheets, David Oldach, Najumuddin Karimjee, Hristo Metev, Yuri Antonovsky, Joseph McDermott Molina, Cristina Mihaela Tanaseanu, Gary Horwith, Analia Mykietiuk, Mimi Floarea Nitu, Brian H. Rowe, Drusilla Scott
Publikováno v:
The Lancet Infectious Diseases. 16:421-430
Summary Background Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality, and treatment recommendations, each with specific limitations, vary globally. We aimed to compare the efficacy and safety of solithromycin